E
EGBOT
Guest
Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015
Source: Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015
HTML:
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.
Source: Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015